BACKGROUND: The incidence of NHL has been steadily rising as apossible result of environmental carcinogens exposure. OBJECTIVE: We aimed at determining whether polymorphisms of drug-metabolizing enzyme CYP1A1increase susceptibility to B-cell NHL. METHODS: Two CYP1A1 genepolymorphisms (3801 [T>C] and 4889 [A>G]) were analyzed in 50 DLBCLpatients and 25 controls using polymerase chain reaction-restriction fragmentlength polymorphism (PCR-RFLP). RESULTS: CYP1A1*2C allele (p<0.001,OR: 6.1, 95% CI: 2.5-14.95) demonstrated highly significant association withDLBCL compared to controls. CONCLUSION: CYP1A1*2C is a risk factor forDLBCL.